EMA Validates Marketing Application for Pfizer–Valneva Lyme Vaccine PF-07307405
核心洞察
The European Medicines Agency (搜索) has validated the Marketing Authorization Application for PF-07307405, Pfizer and Valneva (搜索)'s experimental Lyme disease (搜索) vaccine candidate, triggering formal regulatory review.
The filing rests on the Phase 3 VALOR trial of 9,437 participants aged five and older across high-incidence regions in the US, Canada and Europe.
Topline data released in March 2026 showed efficacy above 70%, but the primary endpoint analysis reported 73.2% efficacy with a 95% confidence interval lower bound of 15.8%, missing the predefined 20% threshold.
The European Medicines Agency (搜索) has validated the Marketing Authorization Application for PF-07307405, the experimental Lyme disease (搜索) vaccine candidate developed by Pfizer Inc. and Valneva (搜索) SE, the companies reported on August 14. Validation marks the formal transition of the program from years of clinical development into European regulatory review, following a collaboration first proposed in a 2020 partnership and license agreement between the US pharmaceutical company and the French biotech.
Phase 3 VALOR Trial Design
The application is based on the Phase 3 VALOR trial, a placebo-controlled, randomized study that enrolled 9,437 participants aged five and older from high-incidence Lyme disease (搜索) locations in the United States, Canada and Europe. Participants received four doses on a phased schedule: one at months 0, 2 and 5–9, followed by a fourth dose approximately one year later, shortly before the start of the next Lyme season.
Topline data released in March 2026 demonstrated efficacy of more than 70% in reducing confirmed Lyme disease (搜索) cases. The vaccine was generally tolerated, and no safety issues were detected in the trial.
Statistical Caveat in the Primary Analysis
The statistical picture was less straightforward than the headline efficacy figure suggests. The first prespecified analysis, which served as the trial's primary endpoint, showed 73.2% efficacy but failed the predefined statistical criterion because the lower bound of the 95% confidence interval was 15.8%, below the required 20%. A second prespecified analysis showed 74.8% efficacy and did meet that threshold.
Development and Commercialization Terms
According to Valneva (搜索), PF-07307405 is the most advanced Lyme disease (搜索) vaccine candidate currently in clinical development — a rare position in the vaccine industry, where new entrants often face competition from existing treatments. Under the terms of the 2020 partnership and license agreement, Pfizer will hold exclusive rights to produce and commercialize the vaccine if it is approved, while Valneva will benefit as a development partner.
Divergent Institutional Profiles
Institutional positioning differs sharply between the two partners, reflecting their very different sizes. Pfizer remains a strong name in the institutional space, with hedge fund ownership stable at 83 funds in the second quarter of 2026, unchanged from the first quarter — consistent with its position as a large, diversified pharmaceutical holding rather than a name driven by a specific pipeline event. Valneva (搜索), by contrast, has little hedge fund exposure, with only 4 funds holding a position in the second quarter, up from 1 in the first quarter, reflecting the smaller partner's continued lack of visibility among institutional investors.